When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Alcohol-use disorder

Last reviewed: 21 Nov 2024
Last updated: 18 Sep 2024
18 Sep 2024

MHRA introduces pregnancy prevention programme for prescribing of topiramate

​The UK Medicines and Healthcare products Regulatory Agency (MHRA) recommends that topiramate is contraindicated in pregnancy and in women of child-bearing potential unless the conditions of a pregnancy prevention programme are fulfilled.[99] This aims to ensure that all women of child-bearing potential are using highly effective contraception, have a pregnancy test to exclude pregnancy before starting topiramate, and are aware of the risks from use of the drug.​

Topiramate is associated with a higher risk of congenital malformations and a high prevalence of babies being born small for gestational age.[99] Topiramate may be also associated with an approximately 2 to 3 times increased risk of intellectual disability, autistic spectrum disorders, and attention deficit hyperactivity disorder.[100]

The European Medicines Agency (EMA) supports these restrictions on the use of topiramate, and also recommends that a pregnancy prevention programme is in place before prescribing topiramate.[101]​​​

See Management: approach

Original source of update

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • withdrawal
  • tolerance
  • increased/decreased liver size, jaundice, ascites
Full details

Other diagnostic factors

  • insomnia
  • erectile dysfunction
  • nicotine-use disorder
  • gastrointestinal distress
  • muscle cramps, pain, tenderness, altered sensory perception
  • hypertension and tachycardia
  • impaired nutritional status
  • broad-based gait
Full details

Risk factors

  • family history of alcohol-use disorder
  • antisocial behaviour (pre-morbid)
  • high trait anxiety level
  • lack of facial flushing on exposure to alcohol
  • low responsivity to the effects of alcohol
  • history of gastric bypass
Full details

Diagnostic investigations

1st investigations to order

  • diagnostic interview
  • alcohol level (breath and blood)
  • Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar)
Full details

Investigations to consider

  • carbohydrate-deficient transferrin (CDT)
  • gamma glutamyl transpeptidase (gamma-GT), alanine aminotransferase (ALT), aspartate aminotransferase (AST)
  • FBC
  • urinary ethyl glucuronide
Full details

Treatment algorithm

ONGOING

at-risk drinking

alcohol-use disorder: non-pregnant adult with no concurrent opioid use or mental health diagnosis

alcohol-use disorder: non-pregnant adult with concurrent opioid use

alcohol-use disorder: non-pregnant adult with concurrent mental health diagnosis

alcohol-use disorder: non-pregnant adolescent

alcohol-use disorder: pregnant

Contributors

Authors

Elisabeth Poorman, MD, MPH

​Assistant Professor of Medicine

Department of Medicine

University of Illinois Chicago

Chicago

IL

Disclosures

EP declares that she has no conflicting interests.

Marlene Martin, MD

Associate Professor of Clinical Medicine

Director, Addiction Care Team

San Francisco General Hospital

University of California, San Francisco

San Francisco

CA

Disclosures

MM is a board member for the National Harm Reduction Coalition and has done consultancy work for the Society of Hospital Medicine.

Sarah Messmer, MD

​Assistant Professor of Clinical Medicine and Pediatrics

University of Illinois Chicago

Chicago

IL

Disclosures

SM declares that she has no conflicting interests.

Acknowledgements

Dr Elisabeth Poorman, Dr Marlene Martin, and Dr Sarah Messmer would like to gratefully acknowledge Dr Colin Drummond, Dr Julie R. Pittman, Dr Philip H. Chung, Dr Robert M. Swift, and Dr Lorenzo Leggio, previous contributors to this topic.

Disclosures

CD, JRP, PHC, and RMS declare that they have no competing interests. LL is an author of a reference cited in this topic.

Peer reviewers

Paul S. Haber, MD

Royal Prince Alfred Hospital and Discipline of Medicine

University of Sydney

Sydney

Australia

Disclosures

PSH is an author of a reference cited in this topic.

Roberta Agabio, MD

Bernard B. Brodie Department of Neuroscience

University of Cagliari

Cagliari

Italy

Disclosures

RA is an author of a number of references cited in this topic.

  • Differentials

    • Other psychiatric disorders
    • Other substance use disorders (especially sedatives)
    More Differentials
  • Guidelines

    • International statistical classification of diseases and related health problems, 11th ed. (ICD-11)
    • Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR)
    More Guidelines
  • Patient information

    Alcohol-use disorder

    More Patient information
  • Calculators

    Alcohol Consumption Screening AUDIT Questionnaire

    More Calculators
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer